A second molecular target that has been identified by Indivior as a priority pathway for the treatment of substance use disorders is the orexin receptor. Two identified orexin receptors (OX1 and ...

Identifying whether components of total energy expenditure (EE) are affected by orexin receptor (OXR1 and OXR2) stimulation or antagonism with dual orexin receptor antagonists (DORAs) has ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

The high-throughput screening for orexin receptor antagonists commenced in ... promoting signals via gamma-aminobutyric acid (GABA) pathways. Clinical trials have demonstrated the efficacy of ...

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical ...

Belsomra is an orexin receptor antagonist. Orexin is a neurotransmitter, a chemical in the brain that attaches to the orexin receptor 1 (OX1R) or orexin receptor 2 (OX2R). These receptors regulate ...